Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Platelet-rich plasma (PRP) is an autologous biological therapy being investigated by the University of the Basque Country (UPV/EHU) for the treatment of acute muscle injuries, specifically in professional football players. The therapy involves concentrating a patient's own platelets, which, upon activation, release a variety of growth factors and bioactive molecules (such as PDGF, TGF-β, and VEGF) that facilitate muscle tissue regeneration and repair. In the clinical trial NCT03676205, the PRP is prepared using the Ortho pras® system and administered via ultrasound-guided intramuscular injections. The study aims to evaluate whether PRP reduces the time to return to play and decreases injury recurrence compared to homeopathic treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on platelet-rich plasma (University of the Basque Country).